CMND

Clearmind Medicine Inc.
CAPPED RATING

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Clearmind Medicine Inc. (CMND) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA 1.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -61.4%
Price Return 12M -99.8%
Catalyst Signal 0.00
Market Cap $2.6M
TTM Revenue N/A
Price / Sales N/A
ROE -107.0%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) C+ (2.5) C (2.4) F (0.6) C+ (2.6) C (2.4)
2026-11-04 B+ (3.7) C+ (2.5) C (2.4) F (0.6) C+ (2.7) C (2.4)
2026-10-28 B+ (3.6) C+ (2.5) C (2.4) D- (0.7) C+ (2.7) C (2.4)
2026-10-21 B+ (3.6) C+ (2.5) C (2.4) F (0.6) C+ (2.6) C (2.4)
2026-10-14 B+ (3.7) C+ (2.5) C (2.4) F (0.6) C+ (2.6) C (2.4)
Page 1 of 4